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Background: Uganda Prisons Service (UPS) is responsible for
thehealth of approximately 32,500 inmates in 233prisons. Inmates
turn over frequently with approximately 100,000 entering/exiting
the system per year; 55% are on remand awaiting trial. The
2011World Health Organization Ugandan TB incidence estimate
was 193/100,000. A 2008 rapid prison assessment estimated TB
prevalence at 654/100,000.However, little is knownabout TB treat-
ment completion in sub-Saharan African prisons. We analyzed
national UPS data to determine TB incidence and treatment com-
pletion in Ugandan prisons.
Methods & Materials: We conducted a retrospective study of
all TB-diagnosed prisoners >18 years of age recorded inUPS TB reg-
isters from June 2011-November 2012. Registerswere analyzed for
TB diagnosis, TB-HIV co-morbidity, and treatment outcome, which
included: i) treatment completion (full prescribed duration docu-
mented), ii) default, iii) death, or iv) failure. We tracked transferred
patients between prisons and recorded those released.
Results: A total of 469prisonerswere diagnosedwith TB, result-
ing in an incidence of 955/100,000 person-years. Ninety-eight
percent were male and 58% [95% conﬁdence interval (CI): 53-62%]
were HIV co-infected. Of 466 prisoners starting TB treatment: 48%
[CI: 43-52%] completed treatment, 43% [CI: 39-48%] defaulted, 5%
[CI: 3-7%] died, and 4% [CI: 2-5%] were still on treatment. During
treatment, of 199 prisoners remaining in the same prison, 12% [CI:
7-16%] defaulted, andof 137prisoners transferred, 53% [CI: 45-62%]
defaulted. Of those defaulting in prison 77% [CI: 69-86%] defaulted
after transfer. Of 130 prisoners released during treatment, 81% [CI:
74-88%] were lost to follow-up. In multivariable analysis, the odds
for TB treatment default were 8.4 times greater among transferred
prisoners than among prisoners who were not transferred dur-
ing TB treatment. Sex, age, HIV status, and disease class were not
associated with default.
Conclusion: TB incidence in Uganda prisons is ﬁve-fold higher
than the general population and treatment completion is lower
(48% versus 67%). Among those defaulting on treatment while
in prison, the majority defaulted after prison transfer. Improved
follow-up is urgently needed within prisons to ensure treatment
completion post-transfer, and public clinic linkage upon release, to
prevent possible development of multidrug-resistant TB.
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Background: Female genital schistosomiasis (FGS) is charac-
terised by genital mucosal lesions called sandy patches causing
inﬂammation and bleeding. Epidemiological evidence of a rela-
tionship between FGS and HIV has been found, but the biological
mechanism behind the association is unknown. Heterosexual
transmission is the most frequent mode of HIV transmission, and
increased expression of the HIV co-receptor CCR5 is likely to cause
enhanced susceptibility to HIV. This study set out to explore CCR5
on CD4+ T-cells in treated and untreated women with FGS.
Methods & Materials: Participants were recruited from a large
school based study inKwaZulu-Natal, SouthAfrica. Bloodandendo-
cervical cytobrush samples were collected from 19 young women
with genital sandy patches detected by colposcopy. The negative
controls consisted of 25 patients without genital lesions and with
no S. haematobium ova found by urine microscopy. From the FGS
positive group, 14 women were seen again 8 months after anti-
schistosomal treatment. Flow cytometry analysis was run with an
activation panel including the parameters CD3, CD4 and CCR5.
The Mann-Whitney U non-parametric test and the Wilcoxon
signed rank test were used when comparing the groups.
Results: The expression of the co-receptor CCR5 on CD4+ cells
was higher in blood samples from FGS positives than FGS nega-
tives (4.7% vs. 1.5%, p =0.018). No signiﬁcant difference was found
in the genital samples (p =0.29). After anti-schistosomal treatment,
the CCR5 expression decreased in both blood and genital samples
(p =0.036 and 0.025, respectively).
Conclusion: The results support the assumption that FGS may
increase the risk of HIV acquisition, not only through damage of
the mucosal epithelial barrier, but also by altering the co-receptor
expression on HIV target cell populations. Anti-schistosomal treat-
ment may modify this effect.
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